Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:
Research and development programs	$ 5,936	$ 5,824	$ 17,896	$ 14,764
Product revenues	11,623	4,797	27,993	13,712
Total revenues	17,559	10,621	45,889	28,476
Costs and operating expenses:
Cost of product revenues	6,598	1,450	14,458	4,400
Research and development	20,571	17,556	63,470	46,191
Sales, general and administrative	25,883	15,708	68,127	46,010
Total costs and operating expenses	53,052	34,714	146,055	96,601
Loss from operations	(35,493)	(24,093)	(100,166)	(68,125)
Other income (expense):
Interest and other income, net	365	347	993	1,066
Interest expense	(3,553)	(1,961)	(9,955)	(5,642)
Loss from equity method investments	(7,201)	(2,360)	(15,313)	(5,541)
Gain (loss) from change in fair value of warrant liability	0	200	688	(425)
Gain (loss) from change in fair value of derivative liabilities	6,205	(2,836)	6,478	(4,386)
Total other income (expense)	(4,184)	(6,610)	(17,109)	(14,928)
Net loss	$ (39,677)	$ (30,703)	$ (117,275)	$ (83,053)
Net loss per share, basic and diluted	$ (0.50)	$ (0.47)	$ (1.57)	$ (1.32)
Weighted average number of common shares used in loss per share computation, basic and diluted	78,866,597	64,811,632	74,716,284	62,782,668